Skip to content
Screener

Biogen BIIB Payments to Acquire Property, Plant, and Equipment

Payments to Acquire Property, Plant, and Equipment at other companies

Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$5.09M+1,613%

Other financials

Income statement

See full
Revenue$2.7B+3.4%
Gross profit$2.0B-4.0%
Operating income$610.7M
Net income$97.5M-84.6%
EPS (diluted)$0.66-84.8%

Balance sheet

See full
Cash & equivalents$1.3B-53.4%
Total debt$7.6B+14.6%
Total equity$18.8B+6.9%
Total assets$32.1B+13.3%

Cash flow

See full
Operating cash flow$448.9M+179%
CapEx$40.9M+53.8%
Free cash flow$408.0M+204%

Valuation

See full
Market cap$30.72B+63.7%
Enterprise value$36.99B+63.7%
P/E34.8×+22.5×
P/S3.1×+1.2×

Profitability

See full
Gross margin74%-1.4pp
Operating margin22.9%
Net margin8.8%-6.5pp
FCF margin26.9%+7.1pp

Returns & leverage

See full
Return on equity4.8%-4.3pp
Debt / equity0.4×0.0×
Current ratio1.9×-0.6×

Where this comes from

Reported directly by Biogen in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

The source filing: Biogen’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 6:36 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000875045-26-000075
Line itemFor the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Other changes in operating assets and liabilities, net(143.0)(75.5)
Net cash flow provided by (used in) operating activities1,094.4420.2
Cash flow from investing activities:
Purchases of property, plant and equipment(92.1)(63.7)
Proceeds from sales and maturities of marketable securities2,140.4
Purchases of marketable securities(896.6)
Acquisition of Apellis, net of cash acquired(5,065.1)
Acquired in-process research and development(135.0)

Item 1. Financial Statements (unaudited)

FAQ

What is Biogen's payments to acquire property, plant, and equipment?
Biogen (BIIB) reported payments to acquire property, plant, and equipment of $40.9M in Q2 2026.
How has Biogen's payments to acquire property, plant, and equipment changed year-over-year?
Biogen's payments to acquire property, plant, and equipment increased by 53.8% year-over-year, from $26.6M to $40.9M.
What is the long-term trend for Biogen's payments to acquire property, plant, and equipment?
Over 4 years (2021 to 2025), Biogen's payments to acquire property, plant, and equipment has grown at a -12.1% compound annual growth rate (CAGR), from $258.1M to $153.8M.

Ask your AI about Biogen's payments to acquire property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude